Carnyx Therapeutics has unveiled CNYX-005, its lead oral sleep candidate, alongside preclinical findings showing increased total sleep time and non-rapid eye movement (NREM) sleep in aged animal models. In the study, aged rats administered with CNYX-005 showed an approximately 1.5- to 2-hour increase in total sleep time… Read More
Michelle L. Mellion, MD, Chief Medical Officer at AstronauTx discusses why small molecules that can restore deep, restorative sleep, could be key to cognitive diseases such as Alzheimer’s. Sleep is the bedrock of good brain health. For a long time, the focus has been on the quantity of sleep. A large body of evidence has… Read More
Centessa Pharmaceuticals has initiated a Phase II trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia. ORX750 was designed using Nxera Pharma technology to directly… Read More
